Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for CMV Prophylaxis After Allo-HSCT
NCT03343600Phase 2Terminated
- Sponsor
- National Taiwan University Hospital
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in cytomegalovirus infection (CMV), sponsored by National Taiwan University Hospital. Started Nov 2017; status: terminated.
02
Drugs
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03343600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343600.